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In the recently published review article by Jagmag et al. (2016), some currently available neurotoxin
based and genetic models of Parkinson’s disease (PD) were described, highlighting the advantages
and disadvantages of preclinical models use to knowledge of PD. The aim of this commentary is to
shed light and to make a reflection on some fundamental issues involving the pathophysiology of
PD and additionally bring to the discussion the animal model of PD based on the administration
of reserpine (RES).
The pathological hallmark of PD involves the progressive loss of neurons in the substantia nigra
pars compacta (SNpc) (Politis and Niccolini, 2015). However, a large body of evidences implies that
the PD pathology is a multisystemic degenerative process that involves other neurotransmitters
such as serotonin (5-HT) and norepinephrine (NE) (Deusser et al., 2015; Liu et al., 2015; Politis
and Niccolini, 2015). It has been demonstrated that the serotonergic system may be the most
critical neurochemical system involved in the pathology of PD, after the dopaminergic system
(Huot and Fox, 2013; Liguori et al., 2015). Changes in serotonin levels may be a contributing factor
to PD symptomatology, in particular, non-motor disturbances (Loane et al., 2013). Patients with PD
show loss of serotonergic neurons in the brainstem raphe nuclei (Braak et al., 2003) and reduced
expression of tryptophan hydroxylase type 2 (TPH2) in the median raphe nucleus (MnR) (Kovacs
et al., 2003). According to Braak staging of PD pathology, serotonergic cell loss in the raphe nuclei is
evident prior to nigrostriatal dopaminergic degeneration. Interestingly, the pattern of serotonergic
loss also seems to be different from that observed in the dopaminergic system (Politis and Loane,
2011). Additionally, other neuronal systems, including noradrenergic locus coeruleus, are also
affected in PD (see review in Jellinger, 1999) and they have been linked to non-motor symptoms
of PD as well. Thereby, these evidences of alterations in the raphe nuclei and catecholaminergic
nuclei highlight the importance of looking beyond the nigrostriatal system in the PD study, in
order to elucidate the underlying mechanisms of deficits of other neurotransmitter systems in
the physiopathology of PD and provide useful information for the development of therapeutic
strategies for this disease.
In the paper, Jagmag et al. (2016) highlight toxins widely used as animal models of PD.
The toxin 1-methyl-4-phenylpyridinium (MPP+), active metabolite of MPTP, is taken up into
dopaminergic terminals by the dopamine transporter (DAT) showing the high affinity for
dopaminergic vesicles (Tipton and Singer, 1993; Dauer and Przedborski, 2003). According Andrew
et al. (1993), 6-hydroxidopamine (6-OHDA) is elevated in the urine and striatum of L-DOPA
treated PD patients, suggesting that 6-OHDA may be an endogenous neurotoxin. This toxin is
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taken up into dopaminergic terminals by DAT as well as taken
up to noradrenergic terminals by the noradrenergic transporter
(NAT). However, a lot of studies using 6-OHDA model given
an inhibitor of NAT as a pretreatment, in order to protect
noradrenergic terminal from 6-OHDA toxicity, precluding the
possibility of PD symptomatology analysis as observed in PD
patients. Pesticide-induced model, particularly rotenone and
paraquat, have substantial challenges of replicability due the high
mortality observed in rats. In addition, these pesticides induce
selective degeneration of dopaminergic neurons as illustrated in
Figure 1.
Jagmag and colleagues did not regard the animal model of PD
induced by Reserpine (RES). Reserpine model was one of the first
models to investigate the pathophysiology and to demonstrate
the therapeutic efficacy of L-DOPA, which remains the gold-
standard treatment for PD (Carlsson et al., 1957). However,
in the 1980s, this toxin became underused due the lack of
selectivity for dopamine was considered a failure of the model.
The RES is an ester alkaloid derived from Rauwolfia species root
that induces symptoms, neurochemical and pharmacological
FIGURE 1 | Schematic representation of molecular events in the dopaminergic (left), noradrenergic (center) and serotoninergic (right) neurons after
administration of the main toxins (MPTP, 6-OHDA, Pesticide and Reserpine) used to induce animal models of PD. The 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) toxin is converted by microglia to 1-methyl-4-phenylpyridinium (MPP+), which is taken up via dopamine transporter (DAT) by dopaminergic
neurons. Once inside neuron, MPP+ acts via inhibition of complex-I of the respiratory chain. Pesticides (Rotenone and Paraquat) are also captured by DAT and have
direct action on the complex-I of the respiratory chain. The 6-Hydroxydopamine (6-OHDA) is a neurotoxin that acts equally on dopaminergic and noradrenergic
neurons, entering in these neurons via DAT and noradrenergic transporter (NAT), respectively. The Reserpine inhibits the vesicular monoamine transporters (VMAT),
inducing a loss of storage capacity of monoamines in synaptic vesicles, monoamines depletion in nerve terminals and in an abnormal cytosolic accumulation of
monoamines. The monoamine oxidase (MAO) catalyze the oxidation of monoamines. Thus, the Reserpine acts on dopaminergic, noradrenergic and serotonergic
neurons. The toxins mentioned above increase the production of reactive oxygen species (ROS), which leads to oxidative stress and cell damage via different routes.
alterations in humans (May and Voegele, 1956) and animals
(Fernandes et al., 2012; Santos et al., 2013; Leão et al., 2015)
similar to those seen in PD patients. It is an inhibitor of vesicular
monoamine transporters (VMAT) as presented in Figure 1.
These transporters play an essential role in the presynaptic
neurotransmission control and in the regulation of cytoplasmic
levels of monoamines. The inhibition of VMAT by reserpine
results in a loss of storage capacity of monoamines in synaptic
vesicles, causing depletion of brain and peripheral monoamines
(Dopamine, NE and 5-HT) leading to oxidative stress (Vergo
et al., 2007). Depletion of monoamines, especially of dopamine,
and oxidative stress are important features of pathophysiology
of PD (Miller and O’Callaghan, 2015). Reserpine is also able
to induce motor and non-motor deficits in rodents, such as
oral dyskinesia, muscle rigidity (Colpaert, 1987; Neisewander
et al., 1994; Fernandes et al., 2012), recognition memory
deficits (Santos et al., 2013; Sarmento et al., 2015), anxiety
and depressive-like behavior (Santos et al., 2013; Antkiewicz-
Michaluk et al., 2014), sleep abnormalities (Chen and Marsh,
2014) and gastrointestinal dysfunction such as gastric dysmotility
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and constipation (Pellegrini et al., 2015). Thus, the reserpine
model is a good mimic of the disease biochemistry and an
important model of choice for early preclinical stages of drug
discovery programmes.
Our research group has proposed that repeated administration
of low doses of reserpine can mimic the progressive nature
of PD (Santos et al., 2013). In this model, the animals
showed cognitive and emotional deficits in the early stages,
even before the onset of motor abnormalities. The non-motor
symptoms have been associated mainly to impairments in the
serotonergic and noradrenergic pathways. The reserpine model
has advantages and disadvantages like others animal models of
PD. The main advantage of this model is its ability to produce
symptoms similar to those observed in the early stages of PD,
may be due to monoamines loss (Dopamine, NE and 5-HT).
However, the underlying mechanisms of reserpine toxic effects
on monoaminergic neurons are not completely understood. We
believe that no single PD model is currently available; on the
other hand, there are distinct models that allow us to investigate
specific mechanisms of PD, since different mechanisms lead to
neuronal cell death in PD and parkinsonian patients exhibit
heterogeneous non-motor and motor symptoms.
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